18 Participants Needed

Gemtuzumab + Midostaurin for Acute Myeloid Leukemia

Recruiting at 2 trial locations
TO
Overseen ByThe Ohio State University Comprehensive Cancer Center
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: OHSU Knight Cancer Institute
Must be taking: Hydroxyurea
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it mentions that no prior systemic anti-AML therapies, except for hydroxyurea, are allowed before starting the study treatment. It's best to discuss your current medications with the study team.

What data supports the effectiveness of the drug combination of Gemtuzumab and Midostaurin for treating Acute Myeloid Leukemia?

Research shows that Midostaurin, when added to standard chemotherapy, improves survival rates in patients with a specific mutation (FLT3) in Acute Myeloid Leukemia. Additionally, Gemtuzumab combined with other drugs has shown effectiveness in achieving remission in high-risk AML patients, suggesting potential benefits when used together with Midostaurin.12345

Is the combination of Gemtuzumab and Midostaurin safe for treating acute myeloid leukemia?

The combination of Gemtuzumab (Mylotarg) and Midostaurin with chemotherapy has been studied for safety in treating acute myeloid leukemia. Common side effects of Gemtuzumab include fever, chills, and low blood cell counts, while Midostaurin's common side effects are fever, nausea, and diarrhea. Both drugs have shown a manageable safety profile in clinical trials.12678

What makes the drug combination of Gemtuzumab and Midostaurin unique for treating acute myeloid leukemia?

This drug combination is unique because it combines Gemtuzumab, which targets CD33-positive leukemia cells, with Midostaurin, an oral drug that inhibits FLT3 and other kinases, potentially improving outcomes for patients with specific genetic mutations in acute myeloid leukemia.123910

What is the purpose of this trial?

This phase I study hopes to explore how safe and tolerable is the combination of gemtuzumab ozogamicin (GO) and midostaurin, with the standard induction therapy (cytarabine and daunorubicin) in patients with newly diagnosed FLT-3 mutated Acute Myeloid Leukemia (AML). GO is FDA approved for the treatment of adults with newly diagnosed CD33 positive AML and used in combination with chemotherapy, cytarabine and daunorubicin. Midostaurin is FDA approved for use with cytarabine and daunorubicin in patients with FLT3-mutated AML. By combining standard induction therapy with GO and midostaurin, our aim is to investigate a novel approach to treating patients with newly diagnosed FLT3-mutated AML.

Research Team

Dr. Uma Borate - Hematology - Columbus, OH

Uma Borate, MD

Principal Investigator

The Ohio State Comprehensive Cancer Center

Eligibility Criteria

This trial is for adults with newly diagnosed FLT-3 mutated Acute Myeloid Leukemia (AML) who can sign consent, have an ECOG status of ≤2, and CD33 positive AML. They must not have had previous AML treatments, no active HIV or hepatitis B/C, and agree to contraception use. Those with severe heart issues, uncontrolled infections or certain allergies are excluded.

Inclusion Criteria

Newly diagnosed AML as confirmed by bone marrow and/or peripheral blood examination as indicated, with: Confirmed CD33 positivity, per institutional standards Presence of FLT3 internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutation as confirmed by next-generation sequencing (NGS) or other molecular method Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN; local laboratory) Alanine aminotransferase (ALT) < 2.5 x ULN Total bilirubin < 2 x ULN (except for patients with known Gilbert's syndrome) Calculated creatinine clearance (according to the Cockcroft-Gault equation) > 40 mL/min OR serum creatinine < 1.5 x the ULN Female patients of childbearing potential must agree to use adequate contraception (2 forms of contraception or abstinence) from the screening visit until 6 months following the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately Male patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from the screening visit until 3 months following the last dose of study treatment. They must also refrain from sperm donation from the screening visit until 90 days following the last dose of study treatment
I can take care of myself but might not be able to do heavy physical work.
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

I have only used hydroxyurea for my AML, no other treatments.
I do not have active HIV, hepatitis B, or hepatitis C.
My AML has spread to my brain or spinal cord, confirmed by a spinal tap.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Induction Therapy

Patients receive cytarabine IV on days 1-7, daunorubicin IV on days 1-3, midostaurin 50mg PO BID on days 8-21, and gemtuzumab ozogamicin IV on specified days depending on dose level

3 weeks

Re-Induction Therapy

Patients with at least 5% bone marrow blasts may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin

4 weeks

Consolidation Therapy

Patients receive high dose cytarabine and gemtuzumab ozogamicin, with midostaurin for up to 2 cycles

8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months

Treatment Details

Interventions

  • Cytarabine
  • Daunorubicin Hydrochloride
  • Gemtuzumab Ozogamicin
  • Midostaurin
Trial Overview The study tests a combination of gemtuzumab ozogamicin (GO) and midostaurin with standard cytarabine and daunorubicin chemotherapy in patients with new FLT-3 mutated AML. It aims to find out if this novel approach is safe and how well patients tolerate it.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (gemtuzumab ozogamicin, cytarabine, daunorubicin)Experimental Treatment5 Interventions
INDUCTION THERAPY: Cytarabine intravenously (IV) on days 1-7, daunorubicin IV on days 1-3 and midostaurin 50 mg orally (PO) twice daily (BID) on days 8-21. Gemtuzumab ozogamicin IV may be given either on days 1, or days 1 and 4 or days 1, 4 and 7. RE-INDUCTION THERAPY: Between days 14 and 21 of Induction Therapy, patients may receive a single 28-day cycle of cytarabine and daunorubicin with or without midostaurin per the treating physician. Patients may also undergo allogeneic stem cell transplantation (SCT) or receive consolidation therapy. CONSOLIDATION THERAPY: PATIENTS \< 60 YEARS: high dose cytarabine (HiDAC) IV on days 1, 3, and 5 and gemtuzumab ozogamicin IV on day 1 of cycle 1 and midostaurin 50 mg PO BID on days 8-21. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. PATIENTS \>= 60 YEARS: Same as above except cytarabine (MiDAC) IV on days 1, 3, and 5.

Cytarabine is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Cytosar-U for:
  • Acute myeloid leukemia
  • Acute lymphocytic leukemia
  • Chronic myeloid leukemia
  • Meningeal leukemia
🇪🇺
Approved in European Union as Depocyt for:
  • Lymphomatous meningitis
🇨🇦
Approved in Canada as Cytosar-U for:
  • Acute myeloid leukemia
  • Acute lymphocytic leukemia
  • Chronic myeloid leukemia

Find a Clinic Near You

Who Is Running the Clinical Trial?

OHSU Knight Cancer Institute

Lead Sponsor

Trials
239
Recruited
2,089,000+

Uma Borate

Lead Sponsor

Trials
7
Recruited
310+

Findings from Research

Midostaurin, when combined with standard chemotherapy (cytarabine and daunorubicin), significantly improves event-free survival, disease-free survival, and overall survival in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML), based on a phase III trial.
The treatment with midostaurin is considered safe, showing no significant difference in overall toxicity compared to placebo, although it was associated with a higher incidence of grade 3 to 5 anemia and rash.
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.Kim, M., Williams, S.[2019]
The combination treatment of gemtuzumab ozogamicin, intermediate-dose cytarabine, and mitoxantrone (MIDAM) resulted in a 63% overall response rate in 62 patients with refractory or relapsed CD33(+) acute myeloid leukemia, with 50% achieving complete remission.
While the MIDAM regimen showed promising efficacy, it also had safety concerns, including a 16% rate of severe hyperbilirubinemia and four early toxic deaths, highlighting the need for further randomized trials to establish its safety and effectiveness as a standard treatment.
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.Chevallier, P., Delaunay, J., Turlure, P., et al.[2019]
In a study of 90 patients with acute myeloid leukemia (AML) in first relapse, combining gemtuzumab ozogamycin (GO) with intermediate- to high-dose cytarabine (IHDAraC) resulted in a significantly higher response rate (68% vs 45%) and improved overall survival (median 35 months vs 6 months) compared to IHDAraC alone.
The benefits of the IHDAraC + GO combination were particularly evident in patients with low- or intermediate-risk cytogenetics, suggesting that this treatment strategy could be more effective for these specific patient groups.
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.Prebet, T., Etienne, A., Devillier, R., et al.[2019]

References

Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. [2019]
Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. [2019]
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. [2019]
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? [2019]
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. [2023]
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia. [2020]
Mylotarg approved for patients with CD33+ acute myeloid leukemia. [2012]
Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program. [2021]
Midostaurin: an emerging treatment for acute myeloid leukemia patients. [2020]
10.United Statespubmed.ncbi.nlm.nih.gov
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security